• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Tue, 23.07.24

ORIGINALS

IMAJ | volume 26

Journal 6, June 2024
pages: 388-394

Hidradenitis Suppurativa Incidence and Prevalence Rates Are Increasing: A Population-based Study

1 Department of Pediatrics, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 2 Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, Israel 3 Faculty of Health Sciences, Siaal Research Center for Family Medicine and Primary Care, Ben Gurion University of the Negev, Beer Sheva, Israel 4 Dermatology Department, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel 5 Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel 6 Dermatology Clinic, Wolfson Medical Center, Holon, Israel 7 Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Summary

Background:

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease associated with a heavy burden of morbidity and cost.

Objectives:

To provide standardized estimates of trends in HS incidence and prevalence among patients in Israel between 2016 and 2019.

Methods:

We conducted a population-based analysis of routinely collected electronic health records data from Clalit Health Services, the largest nationwide public health service provider in Israel. Age- and sex-adjusted rates were reported by using the standard European population as a reference.

Results:

The study included 3488 HS incident cases. The mean ± SD age of onset was 30.3 years and was similar in males and females. HS was more common among Jews with low and medium socioeconomic status. The annual HS incidence rate increased throughout the study period. HS prevalence increased from 0.12% in 2016 to 0.17% in 2019.

Conclusions:

HS prevalence and incidence rates steadily rose among the Israeli population between 2016 and 2019. Awareness of these findings can help provide an optimal allocation of healthcare resources by policymakers and health service providers and prevent delays in diagnosis.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel